STOCK TITAN

STANDARD BIOTOOLS INC - LAB STOCK NEWS

Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.

Standard BioTools Inc. (Nasdaq: LAB), formerly known as Fluidigm Corporation, is at the forefront of biomedical research technology development. The company specializes in providing innovative tools that accelerate the discovery and development of new medicines. Their core technologies include proprietary mass cytometry and microfluidics, catering to the proteomics and genomics markets respectively. With these advanced tools, Standard BioTools enables researchers to gain deep insights into health and disease, facilitating breakthroughs in areas such as oncology, immunology, and immunotherapy.

Headquartered in South San Francisco, Standard BioTools operates globally, serving academic, governmental, pharmaceutical, biotechnology, and clinical laboratories. The company’s products are designed to improve experimental workflows, increase throughput, and reduce costs while maintaining high data quality. Their offerings include sophisticated instruments, software, integrated fluidic circuits (IFCs), high-performance assays for gene expression and genotyping, and next-generation sequencing primers.

In recent developments, Standard BioTools has entered a multi-year collaboration with Bristol Myers Squibb to utilize the SomaScan® Platform in clinical trials, enhancing drug development processes in therapeutic areas like immunology and cardiovascular diseases. Additionally, the company has enhanced its spatial biology capabilities with the launch of the Hyperion™ XTi system, which offers rapid and detailed tissue imaging modes.

Financially, Standard BioTools is focused on operational excellence and disciplined M&A strategies to drive profitable growth. Recent restructuring efforts are projected to save $45-50 million in operational expenses annually by 2025, positioning the company for long-term sustainable growth. The issuance of new common stock shares has also streamlined the company’s capital structure, making it more attractive to investors and potential M&A partners.

Overall, Standard BioTools is committed to providing reliable and repeatable insights that transform scientific discoveries into better patient outcomes, thus playing a crucial role in advancing human health.

Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) completes merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research. The combined company has a formidable capital structure comprising over $500 million in cash and cash equivalents, aiming to self-fund future growth initiatives. The company is targeting large, high growth markets with a diverse portfolio of life sciences tools and is expected to realize $80 million in annual cost synergies by 2026. Key leadership team appointments have also been made.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) announced that its stockholders voted to approve all proposals required for the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders. The merger is expected to close on January 5, 2024, subject to satisfaction of certain customary closing conditions. The company's President and CEO, Michael Egholm, expressed gratitude for the stockholders' support and highlighted the potential for significant shareholder value through enhanced scale and a strengthened balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
-
Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) announced stockholder approval for the transaction with Standard BioTools Inc. (Nasdaq: LAB), creating a diversified leader in life sciences tools. The merger is expected to close on January 5, 2024, subject to certain closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
none
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) demands SomaLogic, Inc. (Nasdaq: SLGC) to answer key questions related to the repeated adjournments of the Special Meeting of Shareholders pertaining to the proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Madryn believes the Board of Directors have betrayed shareholders by delaying the Special Meeting five times for a covert vote-flipping campaign. Madryn has sent a litigation hold to the SomaLogic Board and urges shareholders interested in changing their vote to contact Madryn or the firm’s proxy solicitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
none
-
Rhea-AI Summary
SomaLogic, Inc. (SOMA) faces challenges as fellow shareholders express concerns over the deal consideration and the company's cash assets, leading to last-minute adjournments of a special meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
-
Rhea-AI Summary
Boston Millennia Partners (Nasdaq: BMP) opposes SomaLogic's (Nasdaq: SLGC) merger with Standard BioTools Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) urges shareholders to vote 'AGAINST' the proposed merger between SomaLogic, Inc. (SLGC) and Standard BioTools Inc. (LAB). Four significant shareholders, including the company founder, have openly stated their opposition to the merger, highlighting concerns about undervaluation and a flawed process. The recommendation from proxy advisory service ISS only offered 'cautionary support' for the merger, leaving room for shareholders to vote 'AGAINST' the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) founders Dr. Larry Gold and Dr. Jason Cleveland express opposition to the proposed merger with Standard BioTools, Inc. (Nasdaq: LAB) in a letter to stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
-
Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) responds to Madryn Asset Management's misleading press release regarding the pending merger with Standard BioTools (Nasdaq: LAB).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.54%
Tags
none
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) disclosed that SomaLogic, Inc. (SLGC) failed to engage with Labcorp, a leading strategic partner, before pursuing a merger with Standard BioTools. Madryn calls for a delay of the shareholder meeting due to concerns about maximizing value in the sale process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.54%
Tags
none

FAQ

What is the current stock price of STANDARD BIOTOOLS (LAB)?

The current stock price of STANDARD BIOTOOLS (LAB) is $1.4 as of February 18, 2025.

What is the market cap of STANDARD BIOTOOLS (LAB)?

The market cap of STANDARD BIOTOOLS (LAB) is approximately 524.9M.

What does Standard BioTools Inc. specialize in?

Standard BioTools specializes in developing and selling advanced mass cytometry and microfluidics technologies to help biomedical researchers accelerate the discovery and development of new medicines.

Where is Standard BioTools Inc. headquartered?

Standard BioTools Inc. is headquartered in South San Francisco, California.

What are the main applications of Standard BioTools' technologies?

Standard BioTools' technologies are primarily used in proteomics and genomics applications, with significant focus areas including oncology, immunology, and immunotherapy.

What recent collaborations has Standard BioTools announced?

Standard BioTools recently announced a multi-year collaboration with Bristol Myers Squibb to use the SomaScan Platform in clinical trials for various therapeutic areas.

What is the Hyperion™ XTi system?

The Hyperion™ XTi system is a new spatial biology tool launched by Standard BioTools that offers rapid and detailed tissue imaging modes, enhancing insights into disease progression and therapeutic responses.

How is Standard BioTools working towards financial sustainability?

Standard BioTools has initiated restructuring plans to save $45-50 million in operational expenses annually by 2025 and streamlined its capital structure by issuing new common stock shares.

What are the geographic markets for Standard BioTools?

Standard BioTools serves a global market, with a majority of its revenue derived from the Americas.

Who are the key customers of Standard BioTools?

Key customers include leading academic institutions, government agencies, pharmaceutical companies, biotechnology firms, and clinical laboratories worldwide.

What benefits do researchers gain from using Standard BioTools' products?

Researchers benefit from simplified experimental workflows, increased throughput, reduced costs, and high-quality data, facilitating significant breakthroughs in human health.

Can Standard BioTools' products be used for diagnostic procedures?

No, Standard BioTools products are provided for research use only and are not intended for use in diagnostic procedures.
STANDARD BIOTOOLS INC

Nasdaq:LAB

LAB Rankings

LAB Stock Data

524.88M
365.19M
1.86%
73.34%
3.58%
Medical Devices
Laboratory Analytical Instruments
Link
United States
SOUTH SAN FRANCISCO